Prospera Financial Services Inc Makes New Investment in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Prospera Financial Services Inc purchased a new position in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLLGet Rating) during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 9,536 shares of the specialty pharmaceutical company’s stock, valued at approximately $194,000.

A number of other institutional investors have also modified their holdings of COLL. Allspring Global Investments Holdings LLC acquired a new position in shares of Collegium Pharmaceutical in the fourth quarter valued at approximately $1,514,000. Yousif Capital Management LLC acquired a new position in shares of Collegium Pharmaceutical in the fourth quarter valued at approximately $660,000. Qube Research & Technologies Ltd increased its holdings in shares of Collegium Pharmaceutical by 211.4% in the fourth quarter. Qube Research & Technologies Ltd now owns 81,876 shares of the specialty pharmaceutical company’s stock valued at $1,529,000 after purchasing an additional 55,581 shares during the period. Fisher Asset Management LLC increased its holdings in shares of Collegium Pharmaceutical by 94.6% in the fourth quarter. Fisher Asset Management LLC now owns 39,593 shares of the specialty pharmaceutical company’s stock valued at $740,000 after purchasing an additional 19,244 shares during the period. Finally, KBC Group NV increased its holdings in shares of Collegium Pharmaceutical by 113.3% in the fourth quarter. KBC Group NV now owns 18,721 shares of the specialty pharmaceutical company’s stock valued at $350,000 after purchasing an additional 9,944 shares during the period.

Collegium Pharmaceutical Stock Up 1.7 %

COLL opened at $18.05 on Thursday. The business’s fifty day moving average is $16.96 and its two-hundred day moving average is $17.77. The company has a debt-to-equity ratio of 3.41, a quick ratio of 0.76 and a current ratio of 0.97. The company has a market cap of $612.31 million, a price-to-earnings ratio of 20.28, a PEG ratio of 0.19 and a beta of 0.88. Collegium Pharmaceutical, Inc. has a one year low of $14.04 and a one year high of $25.62.

Collegium Pharmaceutical (NASDAQ:COLLGet Rating) last posted its earnings results on Tuesday, May 10th. The specialty pharmaceutical company reported $0.42 EPS for the quarter, missing analysts’ consensus estimates of $0.82 by ($0.40). The firm had revenue of $83.80 million for the quarter, compared to analysts’ expectations of $78.67 million. Collegium Pharmaceutical had a return on equity of 3.26% and a net margin of 15.68%. The firm’s revenue for the quarter was down 4.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.41 earnings per share. Analysts anticipate that Collegium Pharmaceutical, Inc. will post 4.53 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on COLL. Needham & Company LLC boosted their target price on Collegium Pharmaceutical from $34.00 to $36.00 and gave the company a “buy” rating in a report on Wednesday, April 6th. TheStreet downgraded Collegium Pharmaceutical from a “b-” rating to a “c+” rating in a research note on Monday, April 11th. Finally, StockNews.com downgraded Collegium Pharmaceutical from a “buy” rating to a “hold” rating in a research note on Thursday, May 19th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $33.25.

Collegium Pharmaceutical Profile

(Get Rating)

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment.

Read More

Want to see what other hedge funds are holding COLL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Collegium Pharmaceutical, Inc. (NASDAQ:COLLGet Rating).

Institutional Ownership by Quarter for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.